Akari Therapeutics Plc  (AKTX)
Other Ticker:  
Price: $2.9600 $-0.20 -6.329%
Day's High: $3.07 Week Perf: -5.73 %
Day's Low: $ 2.70 30 Day Perf: 100 %
Volume (M): 27 52 Wk High: $ 5.50
Volume (M$): $ 80 52 Wk Avg: $2.86
Open: $3.05 52 Wk Low: $0.24

 Market Capitalization (Millions $) 924
 Shares Outstanding (Millions) 312
 Employees 15
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -18
 Cash Flow (TTM) (Millions $) 4
 Capital Exp. (TTM) (Millions $) 0

Akari Therapeutics Plc
The companyes focus is to develop therapies that target specific components of the complement system, with the goal of restoring its normal function.

Nomacopan is a dual inhibitor of C5 and LTB4, which are key components of the complement system. In preclinical studies, Nomacopan has demonstrated potent anti-inflammatory and anti-thrombotic effects, which make it a promising candidate for the treatment of various diseases. The drug has also shown a favorable safety profile in clinical trials, with no serious adverse events reported to date.

Akari is currently conducting a Phase III clinical trial of Nomacopan in PNH, which is a rare blood disorder characterized by the destruction of red blood cells. Nomacopan is being evaluated as a potential alternative to the standard of care, eculizumab, which is a monoclonal antibody that targets C If successful, Nomacopan has the potential to offer a more convenient and cost-effective treatment option for PNH patients.

In addition to PNH, Akari is also exploring the use of Nomacopan in other indications, including Guillain-Barr' syndrome, aHUS, and bullous pemphigoid. The companyes pipeline also includes a preclinical program targeting the complement pathway for the treatment of age-related macular degeneration (AMD).

Overall, Akari Therapeutics is an innovative biopharmaceutical company with a unique approach to developing therapies for rare and orphan autoimmune and inflammatory diseases. With a strong focus on the complement system and a promising lead candidate in Nomacopan, the company is well-positioned to create significant value for patients and shareholders alike.

   Company Address: 75/76 Wimpole Street London 0
   Company Phone Number: 8004 0270   Stock Exchange / Ticker: NASDAQ AKTX


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report


Akari Therapeutics Interim CEO Demonstrates Commitment to Shareholder Alignment

Published Wed, Jun 5 2024 12:01 PM UTC

In a recent announcement, biotechnology company Akari Therapeutics Plc (Nasdaq: AKTX) has provided details about the employment contract of its newly appointed Interim President & CEO, Dr. Samir R. Patel. The contract reflects Dr. Patel's strong determination to align his success directly with the success of the company's shareholders, in line with the company's commitment t...

Financing Agreement

Akari Therapeutics Secures $7.6 Million in Successful Initial Closing of Private Placement Financing Round

Published Tue, Jun 4 2024 12:01 PM UTC

Akari Therapeutics Plc Secures $7.6 Million in Successful Initial Closing of Private Placement Financing Round
In recent news, Akari Therapeutics Plc, a biotechnology company focusing on therapies for autoimmune and inflammatory diseases, has announced the successful initial closing of a private placement financing round. The transaction is projected to raise approximate...

Merger and Acquisition

Akari Therapeutics and Peak Bio Join Forces in Transformative Merger, Paving the Way for Revolutionary ADC Technology and GA Treatment

Published Wed, May 1 2024 12:01 PM UTC

Breaking News: Akari Therapeutics and Peak Bio Prioritize ADC Technology and GA Program in Groundbreaking Merger
BOSTON and PLEASANTON, Calif., May 01, 2024 ? Akari Therapeutics, Plc (Nasdaq: AKTX, Akari) and Peak Bio Inc. (OTC: PKBO, Peak) have completed a comprehensive joint portfolio prioritization review, solidifying their focus on Peaks ADC (antibody drug conju...

Merger and Acquisition

Akari Therapeutics and Peak Bio Merge to Create Expanded Pipeline with Novel ADC Toolkit

Published Tue, Mar 5 2024 1:01 PM UTC

BOSTON and PLEASANTON, Calif., March 05, 2024 - Akari Therapeutics, Plc (Nasdaq: AKTX) and Peak Bio Inc. (OTC: PKBO) have officially announced their agreement to merge as equals in an all-stock transaction. This strategic move brings together two leading biotechnology companies, each with a focus on developing advanced therapies for autoimmune and inflammatory diseases....

Financing Agreement

Akari Therapeutics Secures $2 Million Private Placement Financing to Advance Biotechnology Research and Development

Published Tue, Jan 2 2024 1:00 PM UTC

Akari Therapeutics Announces $2 Million Private Placement Financing with Existing Investors
Boston and London, Jan. 02, 2024 - Akari Therapeutics, a leading biotechnology company focused on advanced therapies for autoimmune and inflammatory diseases, announced today the successful completion of a private placement financing with existing investors. The financing, which c...



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com